L-Nutra Unveils Groundbreaking Study on Fasting Mimicking Diets (FMDs) and Chronic Lymphocytic Leukemia
2024-02-13
临床研究
LOS ANGELES, Feb. 13, 2024 /PRNewswire/ -- L-Nutra Inc., premier nutri-technology company spearheading nutri-longevity science and nutri-medicine programs, is excited to announce the release of a pivotal study that explores the potential benefits of fasting mimicking diets (FMDs) in the treatment of chronic lymphocytic leukemia (CLL) in both mice and few human models. CLL is the most prevalent form of leukemia in Western countries, and this groundbreaking research suggests a promising avenue for more effective treatment options.
The study focused on the synergistic effects of cyclic fasting combined with proteasome inhibitorsproteasome inhibitors, experimental medication showing early promise for the treatment of CLL. Researchers clinically assessed CLL mouse models as well as patients undergoing multiple consecutive cycles of the fasting mimicking diet (FMDs) and made several key observations:
Reversible Reductions in Peripheral Blood Lymphocyte Counts: The study revealed that CLL patients experienced reversible reductions in peripheral blood lymphocyte counts with rounds of FMD. Importantly, the reduction in leukemic lymphocytes did not impact normal lymphocytes, indicating a targeted effect on leukemic cells.
Synergistic Impact with Proteasome InhibitorsProteasome Inhibitors: When cyclic fasting mimicking diets (FMDs) were combined with proteasome inhibitorsproteasome inhibitors (bortezomib and carfilzomib) in CLL mouse models, not only was CLL progression delayed, but there was also a significant increase in overall survival. This highlights the impressive impact of strategically using both interventions together in more aggressive cases.
"After multiple successful trials in breast cancer, this early research on CLL suggests that fasting mimicking diets (FMDs) could also play a crucial role in supporting the treatment of the condition in tandem with other therapies," said Dr. Joseph Antoun, CEO of L-Nutra Inc. "While more expansive clinical trials are needed, we are excited to continue exploring how a nourished fast with FMD amplifies the efficacy of proteasome inhibitorsproteasome inhibitors through combined Nutri-Medical therapy."
The findings from this study open up potential new possibilities for CLL treatment strategies and food as medicine in general. The targeted effect of FMD on leukemic cells, combined with the synergistic impact of proteasome inhibitorsproteasome inhibitors, presents a promising avenue for more effective and personalized treatment approaches.
L-Nutra Inc. remains committed to advancing the field of nutri-technology and personalized medicine, and this study marks a significant step forward in understanding the potential of FMDs in CLL treatment, offering hope for improved outcomes and enhanced quality of life for patients.
About L-Nutra:
L-Nutra, premier nutri-technology company, is leading the discovery, design and commercialization of novel Nutrition for Longevity and Nutrition as Medicine programs to enhance human healthspan. L-Nutra has gathered 18 global universities to discover breakthrough nutrition formulations inspired by nature and tailored by Longevity & Medical Sciences to promote healthy aging and advance the development of nutri-therapeutic solutions for age-related diseases. With 32 clinical trials and 100 filed patents, L-Nutra is the world's first Nutri-Tech company using natural ingredients in precision nutrition formulations that enhance the body's own potential to rejuvenate cells, reset metabolism and modify the courses of chronic conditions. For more information visit www.l-nutra.com.
SOURCE L-Nutra Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。